Cell and Gene Therapy Market Size to Grow US$ 93.78 Billion By 2030

The global cell and gene therapy market size was approximate at US$ 18.61 billion in 2022 and is anticipated to grow US$ 93.78 billion by 2030, registering a compound annual growth rate of 22.41% from 2022 to 2030.

The cell and gene therapy market report covering various industry elements and growth trends helpful for predicting the market’s future.

The study provides a strong base for the cell and gene therapy market to be segmented into different segments. In fact, the study also covers the maximum market share during the assessment period by 2030.

This study is based on the partners that are highly competitive, key players as well as their market revenue in the forecast years of 2022 to 2030. There is also a strong focus on product revenues, sales, product categories and even the products that are experiencing the most traction. In this manner, the cell and gene therapy report also speaks about the effectiveness of this market along with its growth during the forecast period of 2030. Other major attributes of the cell and gene therapy market have been studied and analysed across many developments.

Request a Sample Copy of This Report @ https://www.precedenceresearch.com/sample/2445

Cell and Gene Therapy Market  Report Scope 

Also read: LED Driver Market Size to Grow US$ 34.85 Billion By 2030

Research Approach

The comprehensive report on the global cell and gene therapy market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products. Following this, the report provides detailed explanation of objectives of this study and laid down by accredited agencies in the purview of research in the global cell and gene therapy market.

It is followed by market introduction, market dynamics, and an overview of the global market, which includes analysis of market drivers, restraints, and trends pertaining to the global market. Furthermore, Y-o-Y growth analysis with elaborated insights has been provided in order to understand the Y-o-Y growth trend of the global market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Key Players

• Alnylam Pharmaceuticals Inc.
• Amgen Inc.
• Biogen Inc.
• CORESTEM Inc.
• Dendreon Pharmaceuticals LLC.
• Helixmith Co. Ltd.
• JCR Pharmaceuticals Co. Ltd.
• Kolon TissueGene Inc.
• Novartis AG
• Pfizer Inc.

Cell and Gene Therapy Market  Segmentations

By Therapy Type

• Cell Therapy
  • Stem Cells
  • T Cells
  • Dendritic Cells
  • NK Cells
  • Tumor Cells
• Gene Therapy

By Therapeutic class

• Cardiovascular Disease
• Cancer
• Genetic Disorder
• Rare Diseases
• Oncology
• Hematology
• Ophthalmology
• Infectious Disease
• Neurological Disorders

By Delivery Method

• In Vivo
• Ex vivo

By End-Users

• Hospitals
• Cancer Care Centers
• Wound Care Centers
• Others

By Region 

• North America
• Europe
• Asia Pacific
• Latin America
• MEA

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cell and Gene Therapy Market 

5.1. COVID-19 Landscape: Cell and Gene Therapy Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cell and Gene Therapy Market, By Therapy Type

8.1. Cell and Gene Therapy Market, by Therapy Type, 2022-2030

8.1.1. Cell Therapy

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Gene Therapy

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Cell and Gene Therapy Market, By Therapeutic class

9.1. Cell and Gene Therapy Market, by Therapeutic class, 2022-2030

9.1.1. Cardiovascular Disease

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Cancer

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Genetic Disorder

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Rare Diseases

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Oncology

9.1.5.1. Market Revenue and Forecast (2017-2030)

9.1.6. Oncology

9.1.6.1. Market Revenue and Forecast (2017-2030)

9.1.7. Ophthalmology

9.1.7.1. Market Revenue and Forecast (2017-2030)

9.1.8. Infectious Disease

9.1.8.1. Market Revenue and Forecast (2017-2030)

9.1.9. Neurological Disorders

9.1.9.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Cell and Gene Therapy Market, By Delivery Method 

10.1. Cell and Gene Therapy Market, by Delivery Method, 2022-2030

10.1.1. In Vivo

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Ex vivo

10.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Cell and Gene Therapy Market, By End-Users 

11.1. Cell and Gene Therapy Market, by End-Users, 2022-2030

11.1.1. Hospitals

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Cancer Care Centers

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Wound Care Centers

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Others

11.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Cell and Gene Therapy Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.1.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.1.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.1.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.1.5.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.1.5.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.1.5.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.1.6.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.1.6.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.1.6.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.2.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.2.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.2.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.2.5.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.2.5.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.2.5.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.2.6.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.2.6.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.2.6.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.2.7.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.2.7.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.2.7.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.2.8.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.2.8.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.2.8.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.3.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.3.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.3.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.3.5.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.3.5.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.3.5.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.3.6.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.3.6.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.3.6.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.3.7.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.3.7.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.3.7.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.3.8.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.3.8.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.3.8.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.4.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.4.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.4.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.4.5.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.4.5.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.4.5.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.4.6.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.4.6.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.4.6.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.4.7.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.4.7.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.4.7.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.4.8.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.4.8.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.4.8.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.5.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.5.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.5.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.5.5.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.5.5.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.5.5.4. Market Revenue and Forecast, by End-Users (2017-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.5.6.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)

12.5.6.3. Market Revenue and Forecast, by Delivery Method (2017-2030)

12.5.6.4. Market Revenue and Forecast, by End-Users (2017-2030)

Chapter 13. Company Profiles

13.1. Alnylam Pharmaceuticals Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Amgen Inc.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Biogen Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. CORESTEM Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Dendreon Pharmaceuticals LLC.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Helixmith Co. Ltd.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. JCR Pharmaceuticals Co. Ltd.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Kolon TissueGene Inc.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Novartis AG

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Pfizer Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Why should you invest in this report?

If you are aiming to enter the global cell and gene therapy market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for cell and gene therapy are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com